Peter Gøtzsche
PersonMentions
2
Relationships
1
Events
1
Documents
1
Relationship Network
Loading... nodes
Interactive Network: Click nodes or edges to highlight connections and view details with action buttons.
Drag nodes to reposition. Node size indicates connection count.
Line color shows relationship strength: red (8-10), orange (6-7), yellow (4-5), gray (weak).
Use legend and help buttons in the graph for more guidance.
Event Timeline
Interactive Timeline: Hover over events to see details. Events are arranged chronologically and alternate between top and bottom for better visibility.
1 total relationships
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
Asbjørn Hróbjartsson
|
Business associate |
5
|
1 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| 2001-01-01 | N/A | Publication of a systematic review of 114 clinical trials comparing placebo recipients with untre... | Copenhagen (implied) | View |
HOUSE_OVERSIGHT_029929.jpg
This document is a page from a December 12, 2011 issue of The New Yorker, stamped with 'HOUSE_OVERSIGHT_029929', indicating it is part of a Congressional investigation. The text is an article discussing the medical efficacy and scientific definition of the 'placebo effect,' featuring interviews with Robert Temple of the FDA and referencing studies by Danish researchers. While the content is scientific, its inclusion in the oversight file suggests it may be relevant to inquiries regarding medical funding, research practices, or specific individuals (like Epstein) who may have had interests in these scientific fields.
Magazine article (the new yorker) / legal discovery document
2025-11-19
Total Received
$0.00
0 transactions
Total Paid
$0.00
0 transactions
Net Flow
$0.00
0 total transactions
No financial transactions found for this entity. Entity linking may need to be improved.
As Sender
0
As Recipient
0
Total
0
No communications found for this entity. Entity linking may need to be improved.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity